It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...

Two heads are better than one, as the saying goes, and sometimes two instruments, ingeniously recombined, can accomplish ...

Merck and Linde plan to set up specialty chemicals and gases facilities in India to support semiconductor manufacturing.

Merck Foundation Chief Executive Officer (CEO) advanced Cancer Care in Africa by providing 194 Oncology Scholarships in ...

“Our partnership with Opentrons reinforces our focus to automate and digitalize the lab ... new potential therapeutics.” Customers can place orders for workstations and assay kits from Merck ...

Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Epitopea is a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies for use in hard-to-treat cancers by targeting a new class of untapped ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...

Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.